It would seem likely that the ClinStar acquisition is a bolt-on buy which gives PRA a greater global footprint. I don't expect lay-offs in clinical, DM, stats, med writing, reg, etc; areas looked at are finance, hr and i think most of those positions for ClinStar are in Russia, and PRA probably needs them. should be good for PRA and Clinstar employees
interesting. with only two major clinical trial cities (no other city has >50 sites), the circulation of medicines law and the vast cultural differences, not sure why PRA didn't grow Russia organically?